Source: Virtual Congress 2021 – Pharmacology of airway diseases: clinical and laboratory studies



Rating:

Share or cite this content

Citations should be made in the following way:
P. Rogliani (Roma (RM), Italy), J. Ora (Roma (RM), Italy), A. Girolami (Roma (RM), Italy), I. Rossi (Roma (RM), Italy), I. De Guido (Roma (RM), Italy), F. Facciolo (Roma (RM), Italy), M. Cazzola (Roma (RM), Italy), L. Calzetta (Parma (PR), Italy). Adding glycopyrronium to beclomethasone/formoterol combination: synergistic effect on human medium bronchi of COPD donors. 2130

Member's Comments

No comment yet.

Related content which might interest you: Adding glycopyrronium to beclomethasone/formoterol combination: synergistic effect on human small airways of COPD donors Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021 The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD Source: Eur Respir J 2006; 28: Suppl. 50, 212s Year: 2006 Effects of procaterol or salmeterol added to maintenance tiotropium therapy on small airway functions in COPD patients Source: Annual Congress 2010 - COPD: management Year: 2010 Beclomethasone, formoterol and glycopyrronium: ceiling effect in small airways of COPD patients Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD Year: 2020 Beclomethasone, formoterol and glycopyrronium: synergy of dual and triple combinations in an ex vivo model of COPD exacerbation Source: Virtual Congress 2021 – Pharmacology of airway diseases: clinical and laboratory studies Year: 2021 Beclomethasone, formoterol and glycopyrronium: synergism of triple therapy on human airways Source: International Congress 2019 – Advances in COPD pharmacology Year: 2019 Additional benefits of beclomethasone/formoterol extrafine combination treatment on small airways function in asthma Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009 Beclomethasone, formoterol and glycopyrronium: effect on an ex vivo model of COPD exacerbation Source: Virtual Congress 2020 – Scientific advances in airway pharmacology Year: 2020 Qva149, a novel combination of indacaterol and glycopyrronium, demonstrates superior bronchodilation compared with indacaterol or placebo in patients with COPD Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009 The bronchodilatory effect of NVA237 inhaled once daily in patients with COPD Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010 The effect of tiotropium in the treatment of patients with COPD Source: Annual Congress 2010 - COPD: management Year: 2010 Formoterol and tiotropium both improve lung function in stable COPD patients, with some additional benefit when given together Source: Eur Respir J 2006; 28: Suppl. 50, 429s Year: 2006 Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD Source: Eur Respir J 2002; 20: Suppl. 38, 386s Year: 2002 Comparison of the short-term effect of tiotropium (TIO) vs a combination therapy with single inhaler budesonide/formoterol (symbicort) on the degree of pulmonary hyperinflation Source: Eur Respir J 2004; 24: Suppl. 48, 21s Year: 2004 Effects of acute dual bronchodilator treatment (tiotropium + olodaterol) on cardiopulmonary interactions in hyperinflated patients with COPD Source: International Congress 2018 – Advances in exercise physiopathology Year: 2018 Effect of a single dose of formoterol and tiotropium in exercise tolerance in COPD patients: preliminary data Source: Eur Respir J 2003; 22: Suppl. 45, 405s Year: 2003 24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD, and comparison with formoterol Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008 Nebulized formoterol improves airway function in COPD subjects receiving maintenance tiotropium Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008 Effects of low dose inhaled theophylline (ADC4022) co-administered with budesonide on inflammatory markers, lung function, and quality of life in COPD patients Source: Annual Congress 2009 - New drugs for airways disease Year: 2009 Eight weeks of treatment with tiotropium plus fluticasone (t+f) produces an equally effective therapeutic response as salmeterol plus fluticasone (s+f) in subjects with moderate-to-severe asthma Source: Annual Congress 2009 - Towards improving asthma control Year: 2009